Efficacy of 1% Metformin Gel Mixed With PRF in Augmenting Narrow Ridge

NCT ID: NCT05418452

Last Updated: 2022-06-14

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-15
• Study Completion Date: 2023-06-15

Brief Summary

This study aimed to evaluate the efficacy of 1% metformin gel mixed with PRF, in horizontal ridge augmentation with the split-crest technique, for implant placement.

Detailed Description

Dental rehabilitation of edentulous patients with implants has become a common practice in the last few decades. Unfortunately, local conditions of some alveolar ridges of such patients may be challenging for implant placement. One of these conditions is a relevant horizontal deficit that may render dental implants difficult or impossible.

Several solutions are presented to overcome this challenge such as different guided bone regeneration (GBR) techniques and horizontal ridge split. However, these techniques have many shortages that may be overcome by the split crest technique (SCT).

SCT is a procedure for horizontal bone augmentation. It consists of splitting the vestibular and buccal cortical bone, displacing the vestibular cortical bone both in the maxilla or mandible, and separating from the bone marrow, creating a middle gap that is usually occupied mostly by the inserted implants. In such a procedure, ultrasonic bone surgery represents an advantageous alternative technique over conventional surgery using disks and chisels. The ultrasonic device can safely cut mineralized hard tissues such as bone with minor damage. Additionally, at the bone structural level, ultrasonic bone surgery may increase trabecular density as well as bone compression.

To enhance healing the remaining unoccupied space around the implant can be filled with biomaterials such as autologous bone grafts which are considered the gold stander, but unfortunately, site morbidity, as well as, utilizing more than one surgical site may limit its application. Alternatively, other bone substitutes including xenografts, alloplastic, and non-bone graft materials such as Platelet-Rich Fibrin (PRF) have been used in peri-implants space occupation.

PRF is a blood derivative in which platelets have a higher concentration above the baseline level. it can regulate inflammation and stimulate the immune process of chemotaxis. This natural material seems to accelerate the physiological wound healing with or without bone grafts to accelerate new bone formation. (6)In clinical practice, it has already been largely applied as an inexpensive carrier and way to obtain many growth factors (GFs) in physiological proportions. Hence, enhanced bone regeneration and favorable implant healing can be better achieved by using PRF as a graft around dental implants. Some authors reported that the use of PRF as a sole filling material during a simultaneous SCT and implantation stabilized a high volume of natural regenerated bone in the spaces unoccupied by the implants.

Lately, metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects Although PRF is an autogenous material obtained from a patient's blood and contains GFs which promote bone formation, its short time stability may not give it superiority over a commonly used bone graft like xenograft Adding a medical formula with osteogenic potential such as MF to PRF may add to its therapeutic performance and may present a graft material comparable to bone substitutes with the benefit of being cost-effective. Testing this hypothesis constitutes the primary aim of work in the present clinical study.

Conditions

Horizontal Ridge Deficiency

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: QUADRUPLE

Study Groups

metformin

will receive split-crest technique by ultrasonic bone surgery with implant placement and PRF mixed with 1% metformin gel

Group Type: EXPERIMENTAL

Metformin

Intervention Type: DRUG

metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects

control

will receive split-crest technique by ultrasonic bone surgery with implant placement without gap filling.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Metformin

metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Adults (age 18-50) exhibiting initial insufficiently bone ridge.

2. Patients with good oral hygiene.

3. Free from systemic diseases that may influence the outcome of the therapy.

Exclusion Criteria

1. Heavy smokers.

2. Patient treated by immunosuppressive chemotherapy or radiotherapy,

3. Allergy to any material or medication used in the study.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Al-Azhar University

OTHER

Sponsor Role: lead

Responsible Party

Abdelaziz Kamal Aboamo

assistant professor at AlAzharU department of Periodontology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

AlAzhar universty

Cairo, , Egypt

Site Status: RECRUITING

Countries

Egypt

Central Contacts

abdalaziz k aboamo

Role: CONTACT

abdel-azizabo-ammo.209@azhar.edu.eg

+201068128254

Facility Contacts

abdalaziz k aboamo

Role: primary

abdel-azizabo-ammo.209@azhar.edu.eg

+201068128254

abdalaziz aboammo

Role: backup

abdel-azizabo-ammo.209@azhar.edu.eg

+201068128254

Other Identifiers

780/439

Identifier Type: -

Identifier Source: org_study_id